CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −800 | $110.76 | $89K | 191,292 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −104,091 | $107.96 | $11.2M | 87,102 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −21,909 | $108.72 | $2.4M | 65,292 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,000 | 286,004 | ||
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Option exercise · Stock Option (Right to Buy) 10b5-1 | −126,000 | 160,004 | ||
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Option exercise 10b5-1 | +31,249 | $21.77 | $680K | 31,249 |
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −10,354 | $100.22 | $1.0M | 20,895 |
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −15,329 | $101.24 | $1.6M | 5,566 |
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −5,566 | $101.97 | $568K | 0 |
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,249 | 68,751 | ||
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Option exercise 10b5-1 | +30,000 | $17.88 | $536K | 30,000 |
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −16,771 | $80.34 | $1.3M | 13,229 |
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −13,229 | $81.38 | $1.1M | 0 |
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 80,000 | ||
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +3,998 | $8.44 | $34K | 7,998 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +6,908 | $17.88 | $124K | 14,906 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +6,249 | $21.77 | $136K | 21,155 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +9,375 | $22.07 | $207K | 30,530 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −5,428 | $89.72 | $487K | 25,102 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −16,943 | $90.72 | $1.5M | 8,159 |
Page 5 of 24 · 470 trades